We use cookies to ensure that we give you the best experience on our website Learn more

Sep 12, 2018

Society of Hematologic Oncology Sixth Annual Meeting

22 / Experience in autologous stem cell transplantation in elderly multiple myeloma patients

;

multiple myeloma

autologous stem cell transplantation

elderly

high dose chemotherapy

Abstract

Abstract

thumbnail

Keywords

multiple myeloma

autologous stem cell transplantation

elderly

high dose chemotherapy

Abstract

CONTEXT: Most symptomatic multiple myeloma (MM) patients are elderly (>65 years old). Autologous stem cell transplantation (ASCT) is a standard treatment for patients under 65 years old age, whereas it is a procedure that must be individualized for elderly patients, mainly due to increase in toxicity. OBJECTIVE: To determinate effectiveness and safety of ASCT in patients older than 65 yrs in a Latin American country. DESIGN: Retrospective cohort.  We included in the study all myeloma patients who underwent treatment with high dose melphalan and ASCT in our center from January 2008 to November 2017. We compared treatment related mortality and survival between patients ≧ 65 and <65 years old. Kaplan Meier, Cox regression and Cumulative incidence function tests were used with Stata 13 software. MAIN OUTCOMES MEASURES: Primary endpoint was overall survival (OS) and progression free survival (PFS). Secondary endpoints were induction conditioning regimen, time to engraftment, disease response, transplant-related complications and mortality. RESULTS: We included in the analysis 201 patients; 45 patients were older than 65 yrs (7 patients were over 70 years). There were no significant differences in days of admission, response, complications or  transplant related death. OS at five years of the entire cohort was 72.2% [95%CI 62.5-79.8]. There was no significant difference in OS at 3 years between patients younger than 65 years and patients older than 65 (81% [95CI% 72.4-87.2] versus 85.8% [95%CI 64.8-94.8], p=0.17). PFS was 37.7 months [95%CI 24.3-45.1]. The median PFS was 29.6 months [96%CI 20.1-45.1] in the younger group and 44.6 months [95%CI 20.1-48.5] in the elderly ones (p=0.967). There was a tendency to an increase mortality in patients with more comorbidities in both groups CONCLUSIONS: In our experience, consolidating induction treatment with ASCT is possible for patients older than 65 years and even in those older than 70 years. The exclusion of patients should be done according to frailty and comorbidities, not according to chronological age. The correct selection of elderly patients makes transplantation a treatment option, even in developing countries.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.